Daiichi Sankyo
WEBDaiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world.
Daiichi Sankyo - Wikipedia
WEBDaiichi Sankyo Company, Limited (Japanese: 第一三共株式会社, Hepburn: Daiichi Sankyō Kabushiki-gaisha) is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. [3]
About Us - Daiichi Sankyo
WEBDaiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in 29 countries/regions around the world.
Passion for innovation. Compassion for patients. - Daiichi Sankyo …
WEBFor people affected by cancer, Daiichi Sankyo turns hope into possibility. Possibility into reality. Our collective craft is medicine. We’re transforming how cancer and other disease are treated. More than 120 year of heritage inspires us to meet new challenges.
Products - Daiichi Sankyo
WEBDaiichi Sankyo is an innovative global healthcare company based in Japan underpinned by its Purpose: “To contribute to the enrichment of quality of life around the world”.
Press Releases - Daiichi Sankyo US
WEB5 days ago · Patritumab deruxtecan is a specifically engineered potential first-in-class HER3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by Daiichi Sankyo and Merck (NYSE: MRK), known as MSD outside of the United States and Canada.
Company Profile - Daiichi-Sankyo US
WEBDaiichi Sankyo, Inc. is the U.S. arm of Tokyo-based Daiichi Sankyo, Co., Ltd. and a member of the Daiichi Sankyo Group, which spans 20 countries.
Daiichi Sankyo and MSD’s ADC improves progression-free …
WEB4 days ago · Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, an HER3-directed DXd antibody-drug conjugate (ADC) in patients with...
Daiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary
WEB5 days ago · (RTTNews) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in patients with EGFR-mutated non-small cell lung...
Daiichi (4568 JP) Sets Sights on Next Generation of Targeted …
WEB5 days ago · The Japanese cancer drug powerhouse Daiichi Sankyo Co. has its sights on the next generation of targeted oncology drugs, and this time it might not need a partner to get it over the line.